SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the publication of two abstracts for the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO). Both abstracts were accepted for poster presentations, with one of the abstracts also being selected for a poster discussion session. Both of the poster presentations relate to the results of Phase I clinical trials of entrectinib, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumors that harbor activating alterations to TrkA, TrkB, TrkC, ROS1 or ALK, and will be held on May 30, 2015, in Chicago, Illinois.
Help employers find you! Check out all the jobs and post your resume.
